Merck Shares Drop 0.32% with $760M Volume Ranking 124th Amid Pipeline Progress and Market Struggles

On August 20, 2025, Merck (MRK) closed down 0.32% at $84.90, with a trading volume of $0.76 billion, marking a 37.86% decline from the previous day and ranking 124th in market activity. The stock’s underperformance contrasts with its recent pipeline advancements.

Merck’s antibody drug ifinatamab deruxtecan received FDA Breakthrough Therapy Designation for pretreated extensive-stage small cell lung cancer, signaling potential for accelerated regulatory pathways. The European Commission also approved Ogsiveo (nirogacestat) for desmoid tumors, expanding the company’s oncology portfolio. These developments underscore Merck’s focus on high-impact therapies amid competitive pressures in key markets.

However, challenges persist. Analysts highlighted the need for Keytruda, Merck’s flagship immunotherapy, to maintain growth momentum as rivals like Bristol-Myers Squibb and Roche advance competing therapies. Additionally, a global survey by Merck Animal Health revealed gaps in flea and tick prevention awareness, suggesting untapped opportunities in its veterinary segment.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to now delivered moderate returns. The 1-day return was 0.98%, with a total return of 31.52% over 365 days. This indicates the strategy captured some short-term momentum but also reflected market volatility and potential timing risks.